BioSpace News Archive

Rhinomed Completes AUD $3.6M Capital Raising

Rhinomed has successfully undertaken an AUD$3.6M placement to institutional and sophisticated private investors at $0.15 per share.

November 29, 2017
·
2 min read
Bio-Gene Completes $7.1M IPO to List on ASX

Bio-Gene, an agtech development company enabling the next generation of novel insecticides to address insecticide resistance, will list on the ASX today after raising $7.1M in its IPO,

November 29, 2017
·
4 min read
Bedfont Scientific Release: The New Standard in Asthma Management is Here

The NObreath FeNO monitor is the essential tool for GP’s and asthma patients to help improve asthma management.

November 29, 2017
·
5 min read
Genetown

Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders

Approval of a majority of all outstanding shares of Yield10 Bioscience common stock is necessary for this proposal to be approved.

November 29, 2017
·
2 min read
Drug Development

Inovio’s Further Analysis of VGX-3100 Phase IIb Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy

Inovio continues to investigate pre-treatment biomarkers which could identify patients most likely to respond to treatment with VGX-3100, increasing absolute efficacy of the product.

November 29, 2017
·
9 min read
Business

ExplORer Surgical Announcing that it is a Siemens Healthineers Digital Ecosystem Partner

This partnership will allow ExplORer Surgical to expand within the global network of Siemens Healthineers customers.

November 29, 2017
·
2 min read
Biotech Bay

AccelStor Empowers All-Flash Array to Advance Genomics Data Analysis

AccelStor All-NVMe flash array accelerates the time-to-result for Atgenomix’s enterprise-ready bioinformatics solutions.

November 29, 2017
·
4 min read
Business

Vince & Associates, an Altasciences Company, Awarded a $9.5M, Five-Year Contract for Clinical Pharmacology Studies

This contract marks the second time Vince & Associates has been awarded a five-year contract to support NIDA with their clinical pharmacology needs.

November 29, 2017
·
2 min read
Biotech Bay

Cesca Therapeutics Announces Proposed Public Offering of Common Stock

Cesca intends to use the net proceeds from this offering for general corporate purposes, including working capital.

November 29, 2017
·
3 min read
Drug Development

Revance Plans Phase III Program for RT002 Injectable to Treat Cervical Dystonia

Revance’s Phase 3 program will be conducted at multiple sites in the U.S., Canada and Europe, and will be designed to fulfill regulatory submission requirements in both the U.S. and Europe.

November 29, 2017
·
6 min read